Findings

What do systematic reviews say?

959 questions · 987 findings · 78 reviews · Haematology

Sort:Best matchNewestHighest certainty Download CSV

No studies found 256 · 25.9%GRADE not reported 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

Worsening of clinical status (expressed as new need for IMV, admission to ICU, or death by day 28) · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in worsening of clinical status (expressed as new need for IMV,… compared with saline placebo (low certainty).

1 finding from 1 review

Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.67 [0.38, 1.18]
1 study · 241 participants
Low

Early vs late tracheostomy

Evidence from RCTs · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Early versus late tracheostomy in critically ill COVID‐19 patients 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Early vs late tracheostomy

All‐cause mortality · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Early versus late tracheostomy in critically ill COVID‐19 patients 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Early vs late tracheostomy

Overall mortality · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection

Early showed no clear difference in overall mortality compared with late tracheostomy (low certainty).

1 finding from 1 review

Early versus late tracheostomy in critically ill COVID‐19 patients 2023 · Cochrane Headline outcomes only
RR 0.82 [0.52, 1.29]
1 study · 150 participants
Low

Early vs late tracheostomy

Duration of postoperative mechanical ventilation · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Early versus late tracheostomy in critically ill COVID‐19 patients 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Low

Early vs late tracheostomy

Adverse events: all grades · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection

Early showed no clear difference in adverse events (any grade) compared with late tracheostomy (low certainty).

1 finding from 1 review

Early versus late tracheostomy in critically ill COVID‐19 patients 2023 · Cochrane Headline outcomes only
RR 0.94 [0.79, 1.13]
1 study · 150 participants
Low

Early vs late tracheostomy

Incidence of VAP · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection

Early showed no clear difference in ventilator‐associated pneumonia compared with late tracheostomy (low certainty).

1 finding from 1 review

Early versus late tracheostomy in critically ill COVID‐19 patients 2023 · Cochrane Headline outcomes only
RR 1.08 [0.23, 5.2]
1 study · 150 participants
Low

Early vs late tracheostomy

Renal replacement therapy · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Early versus late tracheostomy in critically ill COVID‐19 patients 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Early vs late tracheostomy

Duration of ICU stay · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Early versus late tracheostomy in critically ill COVID‐19 patients 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 150 participants
Low

Early vs late tracheostomy

Evidence from NRSIs · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Early versus late tracheostomy in critically ill COVID‐19 patients 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ESA with or without iron vs no treatment

On‐study mortality3 (Subnet based on 55 studies including 15,074 participants) · patients at any age with solid cancer or haematological malignancy

ESA with or without iron showed no clear difference in on‐study mortality3 (Subnet based on 55 studies including 15,074… compared with no treatment (low certainty).

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
RR 0.13 [0.01, 2.29]
Studies not reported
Low

IV or oral iron alone vs no treatment

Red blood cell transfusions (Subnet based on 69 studies including 18,684 participants) · patients at any age with solid cancer or haematological malignancy

IV or oral iron alone showed no clear difference in red blood cell transfusions (Subnet based on 69 studies including… compared with no treatment (low certainty).

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
RR 0.74 [0.43, 1.28]
Studies not reported
Low

IV or oral iron alone vs no treatment

Overall mortality4 (Subnet based on 71 studies including 21,576 participants) · patients at any age with solid cancer or haematological malignancy

IV or oral iron alone showed no clear difference in overall mortality4 (Subnet based on 71 studies including 21,576… compared with no treatment (low certainty).

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
RR 1.5 [0.63, 3.56]
Studies not reported
Low

IV or oral iron alone vs no treatment

Thromboembolic events · patients at any age with solid cancer or haematological malignancy

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IV or oral iron alone vs no treatment

Thrombocytopenia or haemorrhage5 (Subnet based on 13 studies including 2744 participants) · patients at any age with solid cancer or haematological malignancy

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IV or oral iron alone vs no treatment

Hypertension5 (Subnet based on 24 studies including 8383 participants) · patients at any age with solid cancer or haematological malignancy

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ESA with or without iron vs no treatment

Haemoglobin response (Subnet based on 31 studies including 6985 participants) · patients at any age with solid cancer or haematological malignancy

ESA with or without iron probably leads to higher haemoglobin response (Subnet based on 31 studies including 6985… compared with no treatment (moderate certainty).

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
RR 6.71 [4.93, 9.14]
Studies not reported
Moderate

ESA with or without iron vs no treatment

Red blood cell transfusions (Subnet based on 69 studies including 18,684 participants) · patients at any age with solid cancer or haematological malignancy

ESA with or without iron probably leads to lower red blood cell transfusions (Subnet based on 69 studies including… compared with no treatment (moderate certainty).

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
RR 0.44 [0.31, 0.63]
Studies not reported
Moderate

ESA with or without iron vs no treatment

Overall mortality4 (Subnet based on 71 studies including 21,576 participants) · patients at any age with solid cancer or haematological malignancy

ESA with or without iron showed no clear difference in overall mortality4 (Subnet based on 71 studies including 21,576… compared with no treatment (low certainty).

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
RR 1.46 [0.87, 2.43]
Studies not reported
Low

ESA with or without iron vs no treatment

Thromboembolic events · patients at any age with solid cancer or haematological malignancy

ESA with or without iron showed no clear difference in thromboembolic events5 (Subnet based on 50 studies including 15,408… compared with no treatment (moderate certainty).

1 finding from 1 review

Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer… 2022 · Cochrane Headline outcomes only
RR 1.82 [0.98, 3.41]
Studies not reported
Moderate